2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
03/08/18Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
- Announced positive interim data in the first three patients dosed in ASPIRO, the Phase 1 / 2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM). Plan to dose three additional patients in the first cohort of ASPIRO and to report additional interim data in the second quarter of 2018. - Initiated dosing in VALENS, the Phase 1 / 2 clinical study of AT342 to treat Crigler-Najjar Syndrome. No safety signals observed to date and plan to provide preliminary results in the second q... 
Printer Friendly Version
03/06/18Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference
SAN FRANCISCO, March 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference in Boston, MA.  The presentation is scheduled for Tuesday, March 13, 2018, at 10:00 am E... 
Printer Friendly Version
03/01/18Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
-- Conference Call and Webcast to Follow -- SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call to report its fourth quarter and full year 2017 financial results and provide a corporate update on Thursday, March 8, 2018. The conference call will be hel... 
Printer Friendly Version
02/28/18Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018
SAN FRANCISCO, Feb. 28, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare Disease Day®.  The global theme of this year's Rare Disease Day is research.  Rare disease research contributes to the development of diagnostic tools, treatments and cures, as well as improved ... 
Printer Friendly Version
02/12/18Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
- Preliminary data from VALENS expected to be available in the second quarter of 2018 - Rare Pediatric Disease and Fast Track designations for AT342 granted by FDA SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in VALENS, a Phase 1 / ... 
Printer Friendly Version
02/08/18Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
SAN FRANCISCO, Feb. 8, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY.  The presentation is scheduled for Thursday, February 15, 2018, at ... 
Printer Friendly Version
02/06/18Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical study of AT982 in the fourth quarter of 2018 SAN FRANCISCO, Feb. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing an... 
Printer Friendly Version
01/29/18Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Jan. 29, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the closing of its previously announced underwritten public offering of 6,612,500 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commissions, which included the exerci... 
Printer Friendly Version
01/24/18Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, Jan. 24, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commission.  The gross proceeds to Audentes from the offeri... 
Printer Friendly Version
01/23/18Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, Jan. 23, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer $150.0 million of its common stock in an underwritten public offering.  In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its comm... 
Printer Friendly Version
01/04/18Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
- Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale - Significant improvements in respiratory function as assessed by maximal inspiratory pressure (MIP) - Multiple developmental milestones achieved at 12 weeks in first treated patient SAN FRANCISCO, Jan. 4, 2018 /PRNewswire/ -- Conference call and webcast January 4, 2018 at 8:00am EST Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by diali... 
Printer Friendly Version
01/03/18Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 3, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2018 outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for ... 
Printer Friendly Version